(VIANEWS) – Powell Industries (POWL), InMode Ltd. (INMD), Kiniksa Pharmaceuticals, Ltd. (KNSA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Powell Industries (POWL)
33.7% sales growth and 11.88% return on equity
Powell Industries, Inc., together with its subsidiaries, designs, develops, manufactures, sells, and services custom-engineered equipment and systems for the distribution, control, and monitoring of electrical energy. The company's principal products include integrated power control room substations, custom-engineered modules, electrical houses, medium-voltage circuit breakers, monitoring and control communications systems, motor control centers, and bus duct systems, as well as traditional and arc-resistant distribution switchgears and control gears. Its products have application in voltages ranging from 480 volts to 38,000 volts; and are used in oil and gas refining, onshore and offshore oil and gas production, petrochemical, liquid natural gas terminals, pipeline, terminal, mining and metals, light rail traction power, electric utility, pulp and paper, and other heavy industrial markets. It also provides value-added services, such as spare parts, field service inspection, installation, commissioning, modification and repair, retrofit and retrofill components for existing systems, and replacement circuit breakers for switchgear. The company has operations in the United States, Canada, the Middle East, Africa, Europe, Mexico, and Central and South America. Powell Industries, Inc. was founded in 1947 and is headquartered in Houston, Texas.
Earnings Per Share
As for profitability, Powell Industries has a trailing twelve months EPS of $2.29.
PE Ratio
Powell Industries has a trailing twelve months price to earnings ratio of 35.65. Meaning, the purchaser of the share is investing $35.65 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.88%.
Moving Average
Powell Industries’s value is way higher than its 50-day moving average of $62.18 and way above its 200-day moving average of $44.40.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 64.4% and 460%, respectively.
Volume
Today’s last reported volume for Powell Industries is 187951 which is 76.1% above its average volume of 106729.
2. InMode Ltd. (INMD)
19.3% sales growth and 32.66% return on equity
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Earnings Per Share
As for profitability, InMode Ltd. has a trailing twelve months EPS of $1.93.
PE Ratio
InMode Ltd. has a trailing twelve months price to earnings ratio of 21.05. Meaning, the purchaser of the share is investing $21.05 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.66%.
Moving Average
InMode Ltd. ‘s worth is higher than its 50-day moving average of $39.71 and way above its 200-day moving average of $36.02.
Earnings Before Interest, Taxes, Depreciation, and Amortization
InMode Ltd. ‘s EBITDA is 5.56.
3. Kiniksa Pharmaceuticals, Ltd. (KNSA)
17.9% sales growth and 81.84% return on equity
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Earnings Per Share
As for profitability, Kiniksa Pharmaceuticals, Ltd. has a trailing twelve months EPS of $3.63.
PE Ratio
Kiniksa Pharmaceuticals, Ltd. has a trailing twelve months price to earnings ratio of 4.71. Meaning, the purchaser of the share is investing $4.71 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 81.84%.
Yearly Top and Bottom Value
Kiniksa Pharmaceuticals, Ltd.’s stock is valued at $17.10 at 06:22 EST, way below its 52-week high of $20.65 and way above its 52-week low of $10.14.
Revenue Growth
Year-on-year quarterly revenue growth grew by 165%, now sitting on 280.84M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 105.3% and a negative 366.7%, respectively.
Moving Average
Kiniksa Pharmaceuticals, Ltd.’s worth is above its 50-day moving average of $15.94 and way above its 200-day moving average of $14.14.
4. Park City Group (PCYG)
15.7% sales growth and 12.06% return on equity
Park City Group, Inc., a software-as-a-service provider, designs, develops, and markets proprietary software products in North America. The company offers ReposiTrak MarketPlace, a supplier discovery and B2B e-commerce solution; ReposiTrak Compliance and Food Safety solutions, which reduces potential regulatory and legal risk from their supply chain partners; and ReposiTrak Supply Chain solutions that enables customers to manage relationships with suppliers. It also provides ScoreTracker, Vendor Managed Inventory, Store Level Ordering and Replenishment, Enterprise Supply Chain Planning, Fresh Market Manager, and ActionManager supply chain solutions to manage inventory, product mix, and labor. In addition, the company offers business-consulting services to suppliers and retailers in the grocery, convenience store, and specialty retail industries, as well as professional consulting services. It primarily serves multi-store retail chains, wholesalers and distributors, and their suppliers. The company is headquartered in Murray, Utah.
Earnings Per Share
As for profitability, Park City Group has a trailing twelve months EPS of $0.25.
PE Ratio
Park City Group has a trailing twelve months price to earnings ratio of 38. Meaning, the purchaser of the share is investing $38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.06%.
Sales Growth
Park City Group’s sales growth is 4.3% for the current quarter and 15.7% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.9%, now sitting on 18.87M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Park City Group’s EBITDA is 44.19.
5. Ituran Location and Control Ltd. (ITRN)
14.5% sales growth and 29.44% return on equity
Ituran Location and Control Ltd., together with its subsidiaries, provides location-based services and wireless communications products. The company's Location-Based Services segment provides stolen vehicle recovery and tracking services, which locate, track, and recover stolen vehicles for its subscribers; fleet management services that enable corporate and individual customers to track and manage their vehicles in real time; and personal locator services that allow customers to protect valuable merchandise and equipment. It also offers on-demand navigation guidance, information, and assistance, including the provision of traffic reports and directions, as well as information on the location of gas stations, car repair shops, post offices, hospitals, and other facilities; and Connected Car, service platform includes a back-office application, a telematics device installed in the vehicle, mobile apps for both IOS and Android users, as well as usage based insurance. This segment serves insurance companies and agents, car manufacturers, dealers and importers, cooperative sales channels, and private subscribers. Its Wireless Communications Products segment provides Base Site, a radio receiver that includes a processor and a data computation unit to collect and send data to and from transponders, and to control centers; Control Center, a center consisting of software used to collect data from various base sites, conduct location calculations, and transmit location data to various customers and law enforcement agencies; navigation and tracking devices installed in vehicles; and SMART, a portable transmitter installed in vehicles that sends a signal to the base site enabling the location of vehicles, equipment, or an individual. As of December 31, 2020, it served approximately 17,680,000 end-users in Israel, Brazil, Argentina, Mexico, Ecuador, Colombia, and the United States. The company was incorporated in 1994 and is headquartered in Azor, Israel.
Earnings Per Share
As for profitability, Ituran Location and Control Ltd. has a trailing twelve months EPS of $2.14.
PE Ratio
Ituran Location and Control Ltd. has a trailing twelve months price to earnings ratio of 14. Meaning, the purchaser of the share is investing $14 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.44%.
Moving Average
Ituran Location and Control Ltd.’s worth is way above its 50-day moving average of $26.12 and way above its 200-day moving average of $23.21.
6. CoStar Group (CSGP)
12.3% sales growth and 5.92% return on equity
CoStar Group, Inc. provides information, analytics, and online marketplace services to the commercial real estate, hospitality, residential, and related professionals industries in the United States, Canada, Europe, the Asia Pacific, and Latin America. The company offers CoStar Property that provides inventory of office, industrial, retail, multifamily, hospitality, and student housing properties and land; CoStar Sales, a robust database of comparable commercial real estate sales transactions; CoStar Market Analytics to view and report on aggregated market and submarket trends; and CoStar Tenant, an online business-to-business prospecting and analytical tool that provides tenant information. It also provides Leasing, a tool to capture, manage, and maintain lease data; CoStar Lease Analysis; Public Record, a searchable database of commercially zoned parcels; CoStar Real Estate Manager, a real estate lease administration, portfolio management, and lease accounting compliance software solution; and CoStar Risk Analytics and CoStar Investment. In addition, it offers apartment marketing sites, such as ApartmentFinder.com, ForRent.com, ApartmentHomeLiving.com, WestsideRentals.com, AFTER55.com, CorporateHousing.com, ForRentUniversity.com, Apartamentos.com, and Off Campus Partners; LoopNet Premium Lister; LoopNet Diamond, Platinum, and Gold Ads; LandsofAmerica.com, LandAndFarm.com, and LandWatch.com for rural land for-sale; BizBuySell.com, BizQuest.com, and FindaFranchise.com for operating businesses and franchises for-sale; Ten-X, an online auction platform for commercial real estate; and HomeSnap, an online and mobile software platform, as well as Homes.com, a homes for sale listings site. The company was founded in 1987 and is headquartered in Washington, the District of Columbia.
Earnings Per Share
As for profitability, CoStar Group has a trailing twelve months EPS of $0.87.
PE Ratio
CoStar Group has a trailing twelve months price to earnings ratio of 92.25. Meaning, the purchaser of the share is investing $92.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.92%.
Volume
Today’s last reported volume for CoStar Group is 374559 which is 87.7% below its average volume of 3047160.
Earnings Before Interest, Taxes, Depreciation, and Amortization
CoStar Group’s EBITDA is 12.01.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13%, now sitting on 2.32B for the twelve trailing months.
Moving Average
CoStar Group’s value is under its 50-day moving average of $85.17 and higher than its 200-day moving average of $78.08.
7. Royalty Pharma (RPRX)
11.5% sales growth and 4.66% return on equity
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Earnings Per Share
As for profitability, Royalty Pharma has a trailing twelve months EPS of $0.74.
PE Ratio
Royalty Pharma has a trailing twelve months price to earnings ratio of 40.99. Meaning, the purchaser of the share is investing $40.99 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.66%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Aug 16, 2023, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 2.69%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 0.4%, now sitting on 2.36B for the twelve trailing months.
Volume
Today’s last reported volume for Royalty Pharma is 728138 which is 69.93% below its average volume of 2421520.
8. Regional Management Corp. (RM)
8.8% sales growth and 8.76% return on equity
Regional Management Corp., a diversified consumer finance company, provides various installment loan products primarily to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders in the United States. It offers small and large installment loans; and retail loans to finance the purchase of furniture, appliances, and other retail products. The company also provides insurance products, including credit life, credit accident and health, credit property, vehicle single interest, and credit involuntary unemployment insurance; collateral protection insurance; and property insurance, as well as reinsurance products. In addition, its loans are sourced through branches, centrally managed direct mail campaigns, digital partners, and retailers, as well as its consumer website. As of February 24, 2022, the company operated through a network of approximately 350 branches in 14 states. Regional Management Corp. was incorporated in 1987 and is headquartered in Greer, South Carolina.
Earnings Per Share
As for profitability, Regional Management Corp. has a trailing twelve months EPS of $3.53.
PE Ratio
Regional Management Corp. has a trailing twelve months price to earnings ratio of 7.92. Meaning, the purchaser of the share is investing $7.92 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.76%.
